BTIG Reiterates Buy Rating on Caris Life Sciences, Inc. (CAI)

Market Context

Caris Life Sciences, Inc. operates in the Healthcare sector. The stock currently trades at $18.75 with a market capitalization of $7.5B. The stock has declined 40.5% over the past 52 weeks.

Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Caris Life Sciences, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Caris Life Sciences, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 02, 2026	BTIG	Buy	N/A
May 08, 2026	Citigroup	Buy	N/A
May 08, 2026	JP Morgan	Overweight	N/A
May 08, 2026	BTIG	Buy	N/A
Apr 13, 2026	Jefferies	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View CAI Stock Page